- Home
- CNOB vs ANAB Comparison
CNOB vs ANAB Comparison
Compare CNOB & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNOB
- ANAB
- Stock Information
- Founded
- CNOB 1982
- ANAB 2005
- Country
- CNOB United States
- ANAB United States
- Employees
- CNOB N/A
- ANAB N/A
- Industry
- CNOB Major Banks
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- CNOB Finance
- ANAB Health Care
- Exchange
- CNOB Nasdaq
- ANAB Nasdaq
- Market Cap
- CNOB 910.6M
- ANAB 759.5M
- IPO Year
- CNOB 1996
- ANAB 2017
- Fundamental
- Price
- CNOB $24.31
- ANAB $18.59
- Analyst Decision
- CNOB Buy
- ANAB Buy
- Analyst Count
- CNOB 2
- ANAB 10
- Target Price
- CNOB $28.50
- ANAB $36.38
- AVG Volume (30 Days)
- CNOB 172.6K
- ANAB 892.6K
- Earning Date
- CNOB 04-24-2025
- ANAB 05-08-2025
- Dividend Yield
- CNOB 2.96%
- ANAB N/A
- EPS Growth
- CNOB N/A
- ANAB N/A
- EPS
- CNOB 1.76
- ANAB N/A
- Revenue
- CNOB $250,265,000.00
- ANAB $91,280,000.00
- Revenue This Year
- CNOB $42.90
- ANAB N/A
- Revenue Next Year
- CNOB $30.85
- ANAB $59.43
- P/E Ratio
- CNOB $13.75
- ANAB N/A
- Revenue Growth
- CNOB N/A
- ANAB 432.03
- 52 Week Low
- CNOB $17.07
- ANAB $12.21
- 52 Week High
- CNOB $29.31
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- CNOB 51.23
- ANAB 57.06
- Support Level
- CNOB $23.72
- ANAB $17.50
- Resistance Level
- CNOB $25.40
- ANAB $19.60
- Average True Range (ATR)
- CNOB 0.64
- ANAB 1.37
- MACD
- CNOB 0.15
- ANAB 0.20
- Stochastic Oscillator
- CNOB 63.05
- ANAB 60.56
About CNOB ConnectOne Bancorp Inc.
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).